FW's ZS Pharma named finalist for national business incubator award
FORT WORTH — ZS Pharma, which is developing a drug for patients with kidney and liver disease, has been named one of two finalists for the National Business Incubation Association’s 2013 Outstanding Incubator Client award in the technology category.
The company is an Acceleration client of TECH Fort Worth, a business incubator.
The winner will be announced April 9 at NBIA’s 27th International Conference on Business Incubation in Boston.
"This is huge recognition, for ZS Pharma and for TECH Fort Worth, as the competition for this award is on an international playing field of all clients of technology incubators," said Darlene Ryan, TECH Fort Worth executive director. "The criteria include not only the success of the client, but also the role that the incubator played in helping it get there."
ZS Pharma is a privately-held, specialty pharmaceutical company focused on the development and commercialization of proprietary oral sorbent technology that selectively removes life-threatening toxins in patients suffering from kidney and liver disease.
The company was founded in 2008 and entered the TECH Fort Worth incubation program in 2009, when it received $2 million from the Texas Emerging Technology Fund. In October, the company said it sold $46 million in shares to several new investors.
ZS Pharma conducts some of its work at the University of North Texas Health Science Center in Fort Worth.
NBIA estimates that during 2011, North American incubators assisted about 49,000 start-up companies that provided full-time employment for nearly 200,000 workers and generated annual revenue of almost $15 billion. Approximately 7,000 business incubators operate worldwide.
_ Sandra Baker